drugset / Trial / NCT01540825

First in Man Trial of BI 113608

NCT01540825

Phase 1 Completed 80 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objective of the current study is to investigate the safety and tolerability of BI 113608 in healthy male volunteers following oral administration of single rising doses. A secondary objective is the exploration of the pharmacokinetics of BI 113608 after single dosing.

Timeline

Start
2012-02
Primary completion
2012-05
Completion
2012-05

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 113608 Unknown Oral

Indications

No indication recorded.